Investor Relations
Delivering transparency, performance, and long-term value to our stakeholders.
Key Financial Highlights
Strong financial foundation enabling strategic partnerships and infrastructure expansion.
USD 203M
As of latest update • NSE Listed
244%
5-Year CAGR (FY 2020 – FY 2025)
Zero Debt
Debt-free balance sheet
51%
Long-term promoter commitment
Annual Reports
Annual Report 2024-25
Full-year financial statements, MedTech expansion update, and Board of Directors' report.
Annual Report 2023-24
Revenue growth milestones, WHO-GMP certification upgrade, and international market filings.
Annual Report 2022-23
Post-pandemic recovery, export market expansion, and biosimilar pipeline progress.
Corporate Announcements
Board Meeting Notice – Q4 FY 2025–26 Results
Shukra Pharma shares surge 17,600% in five years amid MedTech expansion
Outcome of Board Meeting – Q3 FY 2025–26 Financial Results
Shukra Pharmaceuticals signs collaboration with Born Medical Robotics Inc.
Disclosure under Regulation 30 – Strategic MedTech Investment
Shukra pioneers advanced robotics in Indian healthcare — DevDiscourse
Board Meeting Notice – Q4 FY 2025–26 Results
Shukra Pharma shares surge 17,600% in five years amid MedTech expansion
Outcome of Board Meeting – Q3 FY 2025–26 Financial Results
Shukra Pharmaceuticals signs collaboration with Born Medical Robotics Inc.
Disclosure under Regulation 30 – Strategic MedTech Investment
Shukra pioneers advanced robotics in Indian healthcare — DevDiscourse
Investor Documents
Access financial reports, disclosures, and key corporate documents.